Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more
Ipsen SA (IPN) - Total Liabilities
Latest total liabilities as of June 2025: €2.60 Billion EUR
Based on the latest financial reports, Ipsen SA (IPN) has total liabilities worth €2.60 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ipsen SA - Total Liabilities Trend (2002–2024)
This chart illustrates how Ipsen SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ipsen SA Competitors by Total Liabilities
The table below lists competitors of Ipsen SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
John Bean Technologies Corporation
NYSE:JBT
|
USA | $1.20 Billion |
|
Rockwool International A/S Series B
LSE:0M0A
|
UK | Dkr706.00 Million |
|
Aris Mining Corporation
NYSE MKT:ARMN
|
USA | $977.30 Million |
|
Hubei Xingfa Chemicals Group Co Ltd
SHG:600141
|
China | CN¥27.41 Billion |
|
Spirit Aerosystems Holdings Inc
NYSE:SPR
|
USA | $10.62 Billion |
|
NKT A/S
PINK:NRKBF
|
USA | $3.66 Billion |
|
Gerdau S.A
MX:GGBN
|
Mexico | MX$32.52 Billion |
|
SG Micro Corp
SHE:300661
|
China | CN¥1.43 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Ipsen SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ipsen SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ipsen SA (2002–2024)
The table below shows the annual total liabilities of Ipsen SA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.26 Billion | -9.68% |
| 2023-12-31 | €2.50 Billion | +10.03% |
| 2022-12-31 | €2.27 Billion | +0.82% |
| 2021-12-31 | €2.25 Billion | +3.38% |
| 2020-12-31 | €2.18 Billion | -14.68% |
| 2019-12-31 | €2.55 Billion | +66.49% |
| 2018-12-31 | €1.53 Billion | -0.14% |
| 2017-12-31 | €1.54 Billion | +44.74% |
| 2016-12-31 | €1.06 Billion | +48.98% |
| 2015-12-31 | €712.40 Million | +10.38% |
| 2014-12-31 | €645.40 Million | +9.09% |
| 2013-12-31 | €591.60 Million | -6.81% |
| 2012-12-31 | €634.84 Million | +2.73% |
| 2011-12-31 | €617.97 Million | +3.17% |
| 2010-12-31 | €598.96 Million | +1.09% |
| 2009-12-31 | €592.52 Million | -15.52% |
| 2008-12-31 | €701.36 Million | +34.41% |
| 2007-12-31 | €521.81 Million | +7.29% |
| 2006-12-31 | €486.37 Million | +51.32% |
| 2005-12-31 | €321.41 Million | -23.83% |
| 2004-12-31 | €421.98 Million | +19.12% |
| 2003-12-31 | €354.24 Million | -18.45% |
| 2002-12-31 | €434.38 Million | -- |